PT  - JOURNAL ARTICLE
AU  - Rudaks, Laura Ivete
AU  - Stevanovski, Igor
AU  - Yeow, Dennis
AU  - Reis, Andre L. M.
AU  - Chintalaphani, Sanjog R.
AU  - Cheong, Pak Leng
AU  - Gamaarachchi, Hasindu
AU  - Worgan, Lisa
AU  - Ahmad, Kate
AU  - Hayes, Michael
AU  - Hannaford, Andrew
AU  - Kim, Samuel
AU  - Fung, Victor S. C.
AU  - Halmagyi, Michael
AU  - Martin, Andrew
AU  - Manser, David
AU  - Tchan, Michel
AU  - Ng, Karl
AU  - Kennerson, Marina L.
AU  - Deveson, Ira W.
AU  - Kumar, Kishore Raj
TI  - Targeted long-read sequencing as a single assay improves diagnosis of spastic-ataxia disorders
AID  - 10.1101/2024.09.04.24312938
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.04.24312938
4099  - http://medrxiv.org/content/early/2024/09/06/2024.09.04.24312938.short
4100  - http://medrxiv.org/content/early/2024/09/06/2024.09.04.24312938.full
AB  - The hereditary spastic-ataxia spectrum disorders are a group of rare disabling neurological diseases. The genetic testing process is complex, and often requires multiple different assays to evaluate the many potential causative genes and variant types, including short tandem repeat expansions, single nucleotide variants, insertions/deletions, structural variants and copy number variants. This can be a protracted process and, even after all avenues are exhausted, many individuals do not receive a genetic diagnosis.Aiming to streamline and improve this process, we developed a targeted long-read sequencing strategy with capacity to characterise genetic variation of all types and sizes within 469 disease-associated genes, in a single assay. We applied this to a cohort of 34 individuals with genetically undiagnosed spastic-ataxia spectrum disorders. An additional five individuals with a known genetic diagnosis were included as positive controls.We identified causative pathogenic variants that would be sufficient for genetic diagnosis in 14/34 (41%) unsolved participants. The success rate was 5/11 (45%) in those who were naïve to genetic testing and 9/23 (39%) in those who were undiagnosed after prior genetic testing, completed on a clinical basis. Short tandem repeat expansions in FGF14 were the most common cause, present in 7/34 (21%). Two individuals (2/34, 6%) had biallelic pathogenic short tandem repeat expansions in RFC1 and one individual had a monoallelic pathogenic short tandem repeat expansion in ATXN8OS/ATXN8. Causative pathogenic sequence variants other than short tandem repeat expansions were found in four individuals, including a heterozygous missense variant in VCP, a heterozygous in-frame deletion in STUB1, a homozygous splicing variant in ANO10, and compound heterozygous missense and nonsense variants in SPG7. In addition to these solved cases, a pathogenic or likely-pathogenic variant with uncertain clinical implications was identified in a further three individuals, including a single individual who was found to have a short tandem repeat expansion in BEAN1 in addition to biallelic expansions in FGF14 within the range of 200-249 repeats.Our results demonstrate the utility of targeted long-read sequencing in the genetic evaluation of patients with spastic-ataxia spectrum disorders, highlighting both the capacity to increase overall diagnostic yield and to streamline the testing pathway by capturing all known genetic causes in a single assay.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Australian Medical Research Futures Fund grants MRF1173594 and MRF2023126 (to I.W.D.). The project receives partial in-kind support from Oxford Nanopore Technologies under an ongoing collaboration agreement.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of St Vincent's Hospital Sydney gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors